Caribou’s allogeneic CAR T builds on early responses, raises durability flags

There was little room for improvement on early responses in the Phase I trial of Caribou’s lead CRISPR-edited CAR T cell following the initial data report last month, but the company delivered even higher response rates in the second round of results. 

It’s becoming clear that editing CAR T cell therapies with CRISPR is one of the most promising strategies for matching — or even surpassing — early efficacy of off-the-shelf cell therapies with that of the autologous products. The question now is whether it can also solve the allogeneic durability issue. ...